China-based WuXi has acquires the sterile filling and freeze-drying plant from Bayer
WuXi Biologics has completed the acquisition deal with Bayer for a drug product manufacturing plant in Leverkusen, Germany.
Under the asset acquisition agreement signed in January, WuXi Biologics has taken over the plant operations, purchased plant equipment and signed a long-term building lease contract. Equipped with a state-of-the-art drug product filling line, the plant will offer sterile filling and freeze drying services of up to 10 million vials per year.
"We are glad to complete this significant deal with Bayer and establish our second site in Europe," said Dr Chris Chen, CEO of WuXi Biologics. "With this new plant in Germany, we can better serve our global clients by implementing the unique manufacturing paradigm of 'Global Dual Sourcing' through our robust and premier-quality supply chain. We will continue to enable our global partners to develop and manufacture biologics that benefit patients worldwide."
To help fight COVID-19 at this critical moment, WuXi Biologics has also donated more than 1,600 masks to medical facilities in Leverkusen.